312 related articles for article (PubMed ID: 9628601)
41. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM
J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009
[TBL] [Abstract][Full Text] [Related]
42. [Porfimer sodium (Photofrin-II)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1995 Aug; 22(9):1271-8. PubMed ID: 7661580
[TBL] [Abstract][Full Text] [Related]
43. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
44. Bacillus Calmette-Guerin-refractory superficial bladder cancers: focus on pretreatment episodes.
Okamura T; Akita H; Tozawa K; Kawai N; Nagata D; Kohri K
Int J Clin Oncol; 2003 Jun; 8(3):168-73. PubMed ID: 12851841
[TBL] [Abstract][Full Text] [Related]
45. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
46. Porfimer sodium-mediated photodynamic therapy in patients with head and neck squamous cell carcinoma.
Hosokawa S; Takahashi G; Sugiyama KI; Takebayashi S; Okamura J; Takizawa Y; Mineta H
Photodiagnosis Photodyn Ther; 2020 Mar; 29():101627. PubMed ID: 31866532
[TBL] [Abstract][Full Text] [Related]
47. Intravesical therapy for superficial bladder cancer.
Baselli EC; Greenberg RE
Oncology (Williston Park); 2000 May; 14(5):719-29; discussion 729-31, 734, 737. PubMed ID: 10853462
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
49. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
[TBL] [Abstract][Full Text] [Related]
50. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
51. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Steinberg GD; Smith ND; Ryder K; Strangman NM; Slater SJ
Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
[TBL] [Abstract][Full Text] [Related]
52. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer.
Wolfsen HC; Hemminger LL; Wallace MB; Devault KR
Aliment Pharmacol Ther; 2004 Nov; 20(10):1125-31. PubMed ID: 15569115
[TBL] [Abstract][Full Text] [Related]
53. Long-term experience with integral photodynamic therapy of TIS bladder carcinoma.
Jocham D; Beer M; Baumgartner R; Staehler G; Unsöld E
Ciba Found Symp; 1989; 146():198-205; discussion 205-8. PubMed ID: 2534070
[TBL] [Abstract][Full Text] [Related]
54. Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source.
Waidelich R; Beyer W; Knüchel R; Stepp H; Baumgartner R; Schröder J; Hofstetter A; Kriegmair M
Urology; 2003 Feb; 61(2):332-7. PubMed ID: 12597941
[TBL] [Abstract][Full Text] [Related]
55. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.
Solsona E; Iborra I; Dumont R; Rubio-Briones J; Casanova J; Almenar S
J Urol; 2000 Sep; 164(3 Pt 1):685-9. PubMed ID: 10953125
[TBL] [Abstract][Full Text] [Related]
56. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
57. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
58. The outcome of conservative treatment of carcinoma in situ of the bladder.
Prout GR; Griffin PP; Daly JJ
J Urol; 1987 Oct; 138(4):766-70. PubMed ID: 3656529
[TBL] [Abstract][Full Text] [Related]
59. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
60. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
